1. Balancing Regulation Against Access to Innovative Pharmaceuticals
Vicki Ehrich
Chief Operating Officer
PIASA
25 July 2007

2. Benefits of local industry investment and presence
Registration and ‘early’ launch of new medicines
Local investment in education and training
Local investment in clinical research
Industry investment in therapeutic areas
Local supply to State Sector
Skills and technology transfer
Pipeline for generic medicines

3. Attracting Pharmaceutical Investment
Financial Incentives
Stimulation of Innovation
Secure IP Framework
Efficient regulatory framework
Large volume / funded market
Access to high level skills pool

4. IP Framework Bolar provision Data protection
Compulsory licensing/parallel imports
Voluntary licensing

5. Large volume / funded market
‹ 1% world market
No developed regional market
No regulatory harmonization
Stagnant private market
Low value government market
Little access to donor demand
Global competitiveness?
Export incentives?

6. Members of PIASA Abbott Laboratories South Africa (Pty) Ltd
Adcock Ingram Healthcare (Pty) Ltd
Alcon Laboratories (Pty) Ltd
Altana Madaus (Pty) Ltd
Astra Zeneca Pharmaceuticals (Pty) Ltd
Bayer Schering Pharma (Pty) Ltd
Boehringer Ingelheim (Pty) Ltd
Bristol-Myers Squibb (Pty) Ltd
Galderma Laboratories (Pty) Ltd
GE Health (Pty) Ltd
Genop Healthcare (Pty) Ltd
GlaxoSmithKline South Africa (Pty) Ltd
iNova Pharmaceuticals (Pty) Ltd
Janssen-Cilag (Pty) Ltd
Key Oncologics (Pty) Ltd
Merck (Pty) Ltd
Novo-Nordisk (Pty) Ltd
Schering-Plough (Pty) Ltd
Sekunjalo Health Care Ltd
Servier Laboratories SA Pty) Ltd
Solvay Pharma (Pty) Ltd
Stiefel Laboratories (Pty) Ltd
Tyco Healthcare (Pty) Ltd
UCB Pharma South Africa (Pty) Ltd
Wyeth South Africa (Pty) Ltd